| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies |
| Delcath Systems, Inc. |
| 1100 Summer Street, Stamford, CT 06905 * (203) 323-8668 |
| Business Description | The company has developed a drug-delivery system, to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver. |
|
Filing Information Not yet | |||
| To Trade As | DCTH (NASSCM) | Industry | Manufacturing (SIC 3841) |
| Type of Stock Offered | Common Shares | Filing Date | 6/16/00 |
| Domestic Shares Filed | 1,200,000 | Filing Price | $6.00 |
| Foreign Shares Filed | 0 | Offering Amount | $7,200,000 |
| Company Shares | 1,200,000 | Est. Expenses | - - |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | 5,437,185 |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Whale Securities Company | Lead Manager | (212) 484-2057 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 6 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/98 | 12/31/99 | 6/30/99 | 6/30/00 | |||
| Revenues | - | - | - | 0.000 | 0.000 | 0.000 | 0.000 |
| Income from Oper. | - | - | - | -2.124 | -0.598 | -0.206 | -0.405 |
| Net Income | - | - | - | -2.050 | -0.573 | -0.200 | -0.392 |
| E.P.S | - | - | - | -2.010 | -0.540 | -0.190 | -0.320 |
| Revenue Growth (%) | - | - | - | - | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -1.09 | - | - | ||||
| Cash Flow - Inv. | 0.00 | - | - | ||||
| Cash Flow - Fin. | 0.80 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 6/30/00 | Financial Ratios | ||||
| Total Assets | 0.81 | Current Assets | 0.78 | Current Ratio | 3.71 |
| Total Liab. | 0.21 | Current Liab. | 0.21 | Debt Ratio | 25.94% |
| Total Equity | 0.60 | Working Cap. | 0.57 | Debt to Equity Ratio | 0.35 |
| Cash | 0.42 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for research and development, introducing the Delcath system into foreign markets and for working capital and general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Morse, Zelnick, Rose & Lander, LLP |
| Bank's Law Firm | Blank, Rome, Comisky & McCauley |
| Registrar/Transfer Agent | American Stock Transfer & Trust Co |
| Auditor | KPMG LLC |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |